Patient Sex in Prescribing CGRP Receptor Antagonists for Migraine

JAMA Neurology JAMA Neurol. Published online February 26, 2024. doi:10.1001/jamaneurol.2023.5835 Michel Lanteri-Minet; Shuu-Jiun Wang; Paolo Martelletti To the Editor In a recent JAMA Neurology Viewpoint,1 Porreca and Dodick raised an important issue by discussing gender differences in outcomes of calcitonin

Generalizability of clinical trial efficacy results to a real-world population: An example in migraine prevention

The Journal of managed care and specialty pharmacy 2023 Dec;29(12):1321-1330.doi: 10.18553/jmcp.2023.29.12.1321. Marie-Ange Paget, Antje Tockhorn-Heidenreich, Mark Belger, Florence Chartier, Michel Lantéri-Minet Abstract Background: Health care decision makers are often concerned about the external validity of randomized controlled trials (RCTs), as their results may not

One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study

The Journal of Headache and Pain 2023 Nov 8;24(1):152. doi: 10.1186/s10194-023-01680-4. M Lanteri-Minet, R Fabre, C Martin, K Pradat, A Alchaar, E Bozzolo, M L Duchene, E K Van Obberghen, A Donnet, D Fontaine Abstract Background: Randomized clinical trials have

Pre- and post-headache phases of migraine: multi-country results from the CaMEO – International Study

The Journal of Headache and Pain 2023 Nov 8;24(1):151. doi: 10.1186/s10194-023-01683-1. Richard B Lipton, Michel Lanteri-Minet, Elizabeth Leroux, Aubrey Manack Adams, Janette Contreras-De Lama, Michael L Reed, Kristina M Fanning, Dawn C Buse Abstract Background: Individuals with migraine frequently experience pre- and post-headache symptoms. This analysis aimed

Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care

Cephalalgia 2023 Jun;43(6):3331024231180611.doi: 10.1177/03331024231180611. Aubrey Manack Adams, Dawn C Buse, Elizabeth Leroux, Michel Lanteri-Minet, Fumihiko Sakai, Manjit S Matharu, Zaza Katsarava, Michael L Reed, Kristina Fanning, Katherine Sommer, Richard B Lipton Abstract Background: The Chronic Migraine Epidemiology and Outcomes-International study provides insight into people with migraine in multiple countries. Methods:

Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study

Cephalalgia 2023 May;43(5):3331024231170807.doi: 10.1177/03331024231170807. Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling, Patricia Pozo-Rosich Abstract Background: Migraine is a disabling neurological disease adversely affecting many aspects of life. Most patients are still required to have failed several older oral

Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data

Cephalalgia 2022 Sep 8;3331024221123058. doi: 10.1177/03331024221123058. Online ahead of print. Michel Lanteri-Minet, Anne Ducros , Clement Francois, Elzbieta Olewinska, Mateusz Nikodem, Laure Dupont-Benjamin Abstract Background: This meta-analysis evaluated the real-world effectiveness of onabotulinumtoxinA (BOTOX®), the first preventive treatment FDA-approved specifically for chronic migraine in 2010.

Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: Pharmacological treatment

Revue Neurologique 2021 Sep;177(7):734-752. A Ducros, S de Gaalon, C Roos, A Donnet, P Giraud, E Guégan-Massardier, M Lantéri-Minet, C Lucas, J Mawet, X Moisset, D Valade, G Demarquay Abstract The French Headache Society proposes updated French guidelines for the